Decentralized Clinical Trials in a Covid-19 Landscape

Published on: 

YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.

• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.